Trial Profile
Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Asia: A Non-interventional Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Nov 2020
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Embolism; Stroke; Thromboembolism
- Focus Adverse reactions
- Acronyms XANAP
- Sponsors Bayer
- 19 Nov 2020 Results from XANTUS, XANAP, GLORIA-AF, ETNA AF-Europe, ETNA AF-Korea/Taiwan, ETNA AF-Japan, comapring stroke and bleeding outcomes in Asia and Europe patients with Nonvalvular Atrial Fibrillation, presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 30 Aug 2017 Results of pooled analysis of three observational studies (XANTUS, XANAP and XANTUS-EL) presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
- 20 May 2016 Status changed from recruiting to completed.